Kura Oncology’s (KURA) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Kura Oncology (NASDAQ:KURA) in a research note issued to investors on Thursday morning,Benzinga reports. HC Wainwright currently has a $40.00 target price on the stock. HC Wainwright also issued estimates for Kura Oncology’s Q1 2025 earnings at ($0.80) EPS, Q3 2025 earnings at ($0.76) EPS and Q4 2025 earnings at ($0.78) EPS.

Several other brokerages have also weighed in on KURA. Scotiabank decreased their price objective on Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating on the stock in a report on Wednesday, January 8th. Jefferies Financial Group decreased their price objective on Kura Oncology from $32.00 to $28.00 and set a “buy” rating on the stock in a report on Thursday, November 21st. Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a report on Monday, December 9th. JMP Securities reissued a “market outperform” rating and set a $28.00 price objective on shares of Kura Oncology in a report on Thursday, February 6th. Finally, StockNews.com lowered Kura Oncology from a “hold” rating to a “sell” rating in a report on Wednesday, November 20th. Four analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $27.13.

Kura Oncology Stock Performance

KURA opened at $7.71 on Thursday. The firm has a market capitalization of $599.56 million, a P/E ratio of -3.27 and a beta of 0.78. The stock’s 50 day moving average price is $8.14 and its two-hundred day moving average price is $13.80. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology has a 12-month low of $6.98 and a 12-month high of $24.17.

Kura Oncology (NASDAQ:KURA) last released its earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.43. The business had revenue of $53.88 million during the quarter, compared to analyst estimates of $57.96 million. On average, equities analysts forecast that Kura Oncology will post -2.44 earnings per share for the current year.

Insider Buying and Selling

In other Kura Oncology news, SVP Thomas James Doyle sold 4,949 shares of Kura Oncology stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the transaction, the senior vice president now owns 88,193 shares in the company, valued at approximately $694,078.91. The trade was a 5.31 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Mollie Leoni sold 4,963 shares of Kura Oncology stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the completion of the transaction, the insider now owns 88,253 shares of the company’s stock, valued at approximately $694,551.11. The trade was a 5.32 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 11,729 shares of company stock worth $92,307 in the last 90 days. 5.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Kura Oncology

Several institutional investors have recently bought and sold shares of KURA. China Universal Asset Management Co. Ltd. raised its position in Kura Oncology by 64.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 14,739 shares of the company’s stock valued at $288,000 after purchasing an additional 5,788 shares during the last quarter. Harbor Capital Advisors Inc. raised its position in Kura Oncology by 21.9% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 47,295 shares of the company’s stock valued at $924,000 after purchasing an additional 8,505 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Kura Oncology by 35.2% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 29,655 shares of the company’s stock valued at $579,000 after buying an additional 7,722 shares during the period. Intech Investment Management LLC acquired a new stake in shares of Kura Oncology in the 3rd quarter valued at $298,000. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Kura Oncology by 2.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 624,952 shares of the company’s stock valued at $12,212,000 after buying an additional 14,106 shares during the period.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.